Respiratory microbiome and metabolome features associate disease severity and the need for doxycycline treatment in children with macrolide-resistant Mycoplasma pneumoniae-mediated pneumonia
Open Access
- 28 July 2025
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Cellular and Infection Microbiology
- Vol. 15, 1537182
Abstract
Introduction: Commensal bacterial community along the upper respiratory tract functions against pathogens. The host determinants of Mycoplasma pneumoniae severity should be identified against the increasing threat of macrolide-resistant M. pneumoniae (MRMP) infection. We hypothesized that respiratory microbiome is involved in the clinical manifestations of M. pneumoniae infection.Methods: From 2017 to 2020, 92 children with MRMP-mediated pneumonia were enrolled among 845 children with community-associated pneumonia. Oropharyngeal samplings were collected within 48 h after admission. We compared respiratory microbiome and metabolites based on patients’ later development of prolonged fever and the need for doxycycline treatment (DT, n = 57) and the cured control without fever or doxycycline treatment (WDT, n = 35) by using 16S rRNA-based sequencing and untargeted metabolome analysis.Results: Significantly higher diversity and different respiratory microbiomes were evaluated in WDT patients in contrast to DT patients. Fusobacterium, Haemophilus, Gemella, Oribacterium, Actinomyces lingnae, Fusobacterium periodonticum, Gemella sanguinis, and Solobacterium moorei were inversely correlated with disease severity. We assumed that metabolites of divergent microbiomes were related to MRMP development. We identified 15 discriminative amino-acid- and fatty-acid-related metabolites in two groups. F. periodonticum abundance was negatively associated with an inflammatory metabolite: a platelet-activating factor. Fusobacterium and Oribacterium were related to the decrease in LysoPE(18:1(9Z)/0:0) and LysoPC(18:1(9Z)).Conclusions: Microbiota dysbiosis with dysregulated inflammatory glycerolphospholipid-related metabolites was related to disease severity and the need for doxycycline treatment in children with MRMP-mediated pneumonia. Anaerobic bacteria metabolites and metabolic pathway could be beneficial therapeutic targets against M. pneumoniae infection.Keywords
This publication has 30 references indexed in Scilit:
- Metabolomic analysis reveals potential biomarkers and the underlying pathogenesis involved in Mycoplasma pneumoniae pneumoniaEmerging Microbes & Infections, 2022
- Clonal spread of macrolide-resistant Mycoplasma pneumoniae sequence type-3 and type-17 with recombination on non-P1 adhesin among children in TaiwanClinical Microbiology and Infection, 2021
- NetCoMi: network construction and comparison for microbiome data in RBriefings in Bioinformatics, 2020
- Association Between the Respiratory Microbiome and Susceptibility to Influenza Virus InfectionClinical Infectious Diseases, 2020
- Mycoplasma pneumoniae Among Children Hospitalized With Community-acquired PneumoniaClinical Infectious Diseases, 2018
- The microbiota protects against respiratory infection via GM-CSF signalingNature Communications, 2017
- DADA2: High-resolution sample inference from Illumina amplicon dataNature Methods, 2016
- Rapid Effectiveness of Minocycline or Doxycycline Against Macrolide-Resistant Mycoplasma pneumoniae Infection in a 2011 Outbreak Among Japanese ChildrenClinical Infectious Diseases, 2012
- Commensal Bacteria Calibrate the Activation Threshold of Innate Antiviral ImmunityImmunity, 2012
- Infectious triggers of asthmaImmunology and Allergy Clinics of North America, 2005